Ambys Medicines Presents New Data Further Validating its Novel Liver Cell Replacement Therapy Platform at the ASGCT Annual Meeting
Retrieved on:
Wednesday, May 18, 2022
Health, Genetics, General Health, Clinical Trials, Research, Science, Biotechnology, Therapy, Death, Cirrhosis, Cas9, Transplant, Genetic engineering, Aminoacyl tRNA synthetases, class I, CTL, Patient, Kinetics, Gene editing, FIX, Liver, Society, FRG, Hyperfunction, Cell, Gene, Mouse, Lists of diseases, Liver disease, NK, Instagram, Hepatocyte, Amby Burfoot, LinkedIn, Twitter, Factor IX, Liver failure, Institute of Liver and Biliary Sciences, Pharmaceutical industry, Medical imaging, Vaccine
Ambyss proprietary platform enables the first and only development and manufacture of functional human hepatocytes, unlocking the full potential of hepatocyte replacement therapy.
Key Points:
- Ambyss proprietary platform enables the first and only development and manufacture of functional human hepatocytes, unlocking the full potential of hepatocyte replacement therapy.
- "Our new data show that Ambys is capable at efficient genetic modification of primary human hepatocytes, unleashing a powerful combination of cell and gene therapy in hepatocytes, said Ron Park, M.D., Chief Executive Officer of Ambys Medicines.
- "The universal hepatocyte data presented today coupled with the data on our hyperfunctional human hepatocyte program and in vivo bioreactor platform presented earlier this week further validate our breakthrough replacement cell therapy approach for severe liver diseases.
- Ambys Medicines is focused on pioneering cell replacement therapies for patients with liver failure.